Immune factors or depression? Fatigue correlates in Parkinson's disease;¿Factores inmunes o depresión? La fatiga relacionada con la enfermedad de Parkinson

Revista de Neurologia

Volumn 45, Issue 12, 2007, Pages 725-728

  Katsarou, Z ^a   Bostantjopoulou, S ^b   Hatzizisi, O ^c   Giza, Evangelia ^a,d   Soler Cardona, A ^a   Kyriazis, G ^c  

^a Hospital Hippokration   (Greece)

^b Hospital G Papanicolaou   (Costa Rica)

^c Hospital G Papanicolaou   (Spain)

^d NONE   (Greece)

Author keywords

Cytokyines; Depression; Fatigue; FSS; Parkinson's disease; T B lymphocytes

Indexed keywords

ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; IL6 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; ANTIGEN ANTIBODY COMPLEX; ARTICLE; B LYMPHOCYTE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; FATIGUE; FATIGUE SEVERITY SCALE; FEMALE; HELPER CELL; HUMAN; MALE; MOTOR DYSFUNCTION; NATURAL KILLER CELL; PARKINSON DISEASE; PATHOGENESIS; RATING SCALE; SUPPRESSOR CELL; T LYMPHOCYTE; AGED; BLOOD; HOSPITALIZATION; IMMUNOLOGY; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

AGED; DEPRESSION; FATIGUE; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37549056264     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4512.2007496     Document Type: Article

References (44)

1. Krupp LB. Fatigue. Philadelphia: Butterworth-Heinemann; 2003.
2. Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler 2003; 9: 219-27.
3. Sood A, Moynihan TJ. Cancer-related fatigue: an update. Curr Oncol Rep 2005; 7: 277-82.
4. Friedman JH, Brown RG, Comella C, Garber CE, Krupp LB, Lou JS, et al. Working Group on Fatigue in Parkinson's Disease. Fatigue in Parkinson's disease: a review. Mov Disord 2007; 22: 297-308.
5. Herlofson K. The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurol Scand 2003; 107: 1-6.
6. Hunot S, Hirsch E. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003; 53 (Suppl 3): S49-60.
7. McGeer P, McGeer E. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord 2004; 10 (Suppl 1): S3-7.
8. Nagatsu T, Sawada M. Inflammatory process in Parkinson's disease: role of cytokines. Curr Pharm Des 2005; 11: 999-1016.
9. Hughes AJ, Daniel SE, Kilford I, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
10. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the mental state of patients for the clinicians. J Psychiatr Res 1975; 12: 189-98.
11. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989; 46: 1121-3.
12. Katsarou Z, Bostantjopoulou S, Peitsidou E, Kourtesi G, Tsipropoulou, V, Kafantari A. Fatigue assessment in Parkinson's disease. Encephalos 2007; 44: 150-7.
13. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, II. Florham Park: MacMillan Headcare; 1987. p. 293-304.
14. Hoehn M, Yahr M. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42.
15. Donias S, Demertzis I. Standardized assessment of depression by means of the Beck Depression Inventory. Proceedings of the 5th Greek Conference for Neurology and Psychiatry 1983; 1: 486-92.
16. Friedman J, Friedman H. Fatigue in Parkinson's disease. Neurology 1993; 43: 2016-8.
17. Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistent symptom in patients with Parkinson disease? Neurology 2004; 63: 1908-11.
18. Larsen JP, Karlsen K, Tandberg E. Clinical problems in non-fluctuating patients with Parkinson's disease: a community-based study. Mov Disord 2000; 15: 826-9.
19. Lou J, Kearns G, Oken B, Sexton G, Nutt J. Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Mov Disord 2001; 16: 190-6.
20. Starkstein SE, Merello M. Psychiatric and cognitive disorders in Parkinson's disease. Cambridge: Cambridge University Press; 2002.
21. Herlofson K, Larsen JP. Measuring fatigue in patients with Parkinson's disease -the Fatigue Severity Scale. Eur J Neurol 2002; 9: 595-600.
22. Abe K, Takanashi M, Yanagihara T. Fatigue in patients with Parkinson's disease. Behav Neurol 2000; 12: 103-6.
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4 ed (DSM-IV). Washington DC: APA; 1994.
24. Schapira AH. Evidence for mitochondrial dysfunction in Parkinson's disease: a critical appraisal. Mov Disord 1994; 9: 125-38.
25. Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 2005; 46: 227-32.
26. Katsarou Z, Bostantjopoulou S, Gerasimou G, Kafantari A, Peitsidou E, Kourtesi G. Fatigue in Parkinson's disease: relation to clinical parameters and 123 I-FP-CIT SPECT data. Parkinsonism Relat Disord 2005; 11 (Suppl 2): S150.
27. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64: 604-11.
28. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104: 788-93.
29. Kozora E. Fatigue in systemic lupus erythematosus and related immune disorders. In DeLuca J, ed. Fatigue as a window to the brain. Cambridge, Mass: MIT Press; 2005. p. 243-64.
30. Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE. The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 2007; 21: 413-27.
31. Kelley KW, Bluthé RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, et al. Cytokine-induced sickness behavior. Brain Behav Immun 2003; 17 (Suppl 1): S112-8.
32. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007; 21: 153-60.
33. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-α and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999; 100: 34-41.
34. Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y. Increase in peripheral CD4 Bright+ CD8 Dull+T cells in Parkinson disease. Arch Neurol 2001; 58: 1580-3.
35. Bas J, Calopa M, Mestre M, Molleví DG, Cutillas B, Ambrosio S, et al. Lymphocyte populations in Parkinson's disease and in rat models of Parkinsonism. J Neuroimmunol 2001; 113: 146-52.
36. Selikhova M, Kushlinskii N, Lyubimova N, Gusev E. Impaired production of plasma interleukin-6 in patients with Parkinson's disease. Bull Exp Biol Med 2002; 33: 81-3.
37. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain 2005; 128: 2665-74.
38. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 2005; 11: 493-498.
39. Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm (Suppl) 2006; 70: 373-81.
40. Perry VH. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 2004; 18: 407-13.
41. Blum-Degen D, Müller T, Kuhn W, Gerlach M, Przuntek H, Riederer P, et al. Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202: 17-20.
42. Müller T, Blum-Degen D, Przuntek H, Kuhn W. Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol Scand 1998; 98: 142-4.
43. Mattila KM, Rinne JO, Lehtimäki T, Röyttä M, Ahonen JP, Hurme M. Association of an interleukin 1β gene polymorphism (-511) with Parkinson's disease in Finnish patients. J Med Genet 2002; 39; 400-2.
44. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, et al. Inflammatory markers and the risk of Alzheimer disease. The Framingham Study. Neurology 2007; 68: 1902-8.